comparemela.com
2
3
4
5
6
7
8
Latest Breaking News On - Crossject - Page 1 : comparemela.com
Crossject reports audited financial results for 2023
Dijon, France April 25, 2024 Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency.
Natasha-drapeau
Sophie-baumont
Us-biomedical-advanced-research
Development-authority
Euronext
Research-tax-credit
Cohesion-bureau
France-april
Advanced-research
Paris-stock-exchange-alcj
Crossject
Crossject to host a business briefing on commercial
Dijon, France, February 1, 2024 18:15 CET - Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free.
France
Sophie-baumont
Natasha-drapeau
Patrick-alexandre
Development-authority
Cohesion-bureau
Biomedical-advanced-research
Euronext
Syneos-health
Executive-chairman
Olivier-gire
Specialty-pharma
Crossject to present at Biotech Showcase on January 9 at
Press Release Crossject to present at Biotech Showcase on January 9 at 16:30 PT Dijon, France, January 9, 2024 Crossject (ISIN: FR0011716265;.
San-francisco
California
United-states
France
Sophie-baumont
Natasha-drapeau
Development-authority
Euronext
Cohesion-bureau
Biomedical-advanced-research
Biotech-showcase
Ballroom-level
Crossject signs ZEPIZURE® commercialization agreement for
Crossject to receive up to €1 million on marketing approvals, plus a markup on sales linked to gross margin Agreement, with undisclosed strategic partner,.
Denmark
Finland
France
Norway
United-kingdom
New-zealand
Australia
Sweden
Germany
Patrick-alexandre
Natasha-drapeau
Sophie-baumont
Crossject reports financial results and business highlights
Press Release Crossject reports financial results and business highlights for first half of 2023 Strong progress in bringing drugs for use in.
New-zealand
France
Saclay
France-general
Australia
Paris
French
Sophie-baumont
Daniel-teper
Patrick-alexandre
Daniel-teperas
Natasha-drapeau
vimarsana © 2020. All Rights Reserved.